Intranasal Technology

Intranasal Technology, Inc. (ITI) was a specialty pharmaceutical company focused on the development of nasally administered drugs for acute medical conditions. The company utilized proprietary delivery technologies to provide rapid-onset alternatives to intravenous or oral medications, primarily in the fields of pain management and sedation. Its lead product candidates included nasal formulations of fentanyl, midazolam, and ketamine, designed to offer non-invasive and fast-acting relief for patients. In 2010, the company was acquired by Par Pharmaceutical, which sought to leverage ITI's nasal delivery platform to expand its specialty drug portfolio.